Sicca Syndrome (Sjogren) - Pipeline Review, H1 2017

Market: Pharmaceuticals and Healthcare

Global, 104 pages report, published by Global Markets Direct

Keywords : Sicca Syndrome (Sjogren) Therapeutic Products under Development, Key Players in Sicca Syndrome (Sjogren) Therapeutics, Sicca Syndrome (Sjogren) Pipeline Overview, Sicca Syndrome (Sjogren) Pipeline, Sicca Syndrome (Sjogren) Pipeline Assessment

Report ThumbnailJune-2017
Sicca Syndrome (Sjogren) - Pipeline Review, H1 2017

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Sicca Syndrome (Sjogren) - Pipeline Review, H1 2017, provides an overview of the Sicca Syndrome (Sjogren) (Immunology) pipeline landscape.

Sjogren’s syndrome is an autoimmune disease. It involves inflammation of glands and other tissues of the body. Symptoms include skin rashes or dry skin, vaginal dryness, persistent dry cough, prolonged fatigue, dry eye, dry mouth, joint pain, swelling and stiffness. Predisposing factors include age, sex and rheumatic disease.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Sicca Syndrome (Sjogren) - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Sicca Syndrome (Sjogren) (Immunology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Sicca Syndrome (Sjogren) (Immunology) pipeline guide also reviews of key players involved in therapeutic development for Sicca Syndrome (Sjogren) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 14, 4, 7 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.

Sicca Syndrome (Sjogren) (Immunology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Sicca Syndrome (Sjogren) (Immunology).
- The pipeline guide reviews pipeline therapeutics for Sicca Syndrome (Sjogren) (Immunology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Sicca Syndrome (Sjogren) (Immunology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Sicca Syndrome (Sjogren) (Immunology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Sicca Syndrome (Sjogren) (Immunology)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Sicca Syndrome (Sjogren) (Immunology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Sicca Syndrome (Sjogren) (Immunology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
  • List of Figures
  • Number of Products under Development for Sicca Syndrome (Sjogren), H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Number of Products by Top 10 Targets, H1 2017
  • Number of Products by Stage and Top 10 Targets, H1 2017
  • Number of Products by Top 10 Mechanism of Actions, H1 2017
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017
  • Number of Products by Routes of Administration, H1 2017
  • Number of Products by Stage and Routes of Administration, H1 2017
  • Number of Products by Top 10 Molecule Types, H1 2017
  • Number of Products by Stage and Top 10 Molecule Types, H1 2017
  • List of Tables
  • Number of Products under Development for Sicca Syndrome (Sjogren), H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017
  • Number of Products under Development by Universities/Institutes, H1 2017
  • Products under Development by Companies, H1 2017
  • Products under Development by Companies, H1 2017 (Contd..1), H1 2017
  • Products under Development by Universities/Institutes, H1 2017
  • Number of Products by Stage and Target, H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017
  • Number of Products by Stage and Route of Administration, H1 2017
  • Number of Products by Stage and Molecule Type, H1 2017
  • Sicca Syndrome (Sjogren) - Pipeline by Akari Therapeutics Plc, H1 2017
  • Sicca Syndrome (Sjogren) - Pipeline by Amgen Inc, H1 2017
  • Sicca Syndrome (Sjogren) - Pipeline by Atlantic Bio Sci LLC, H1 2017
  • Sicca Syndrome (Sjogren) - Pipeline by Bristol-Myers Squibb Company, H1 2017
  • Sicca Syndrome (Sjogren) - Pipeline by Eli Lilly and Company, H1 2017
  • Sicca Syndrome (Sjogren) - Pipeline by F. Hoffmann-La Roche Ltd, H1 2017
  • Sicca Syndrome (Sjogren) - Pipeline by Galapagos NV, H1 2017
  • Sicca Syndrome (Sjogren) - Pipeline by Gilead Sciences Inc, H1 2017
  • Sicca Syndrome (Sjogren) - Pipeline by GlaxoSmithKline Plc, H1 2017
  • Sicca Syndrome (Sjogren) - Pipeline by Immunwork Inc, H1 2017
  • Sicca Syndrome (Sjogren) - Pipeline by MedImmune LLC, H1 2017
  • Sicca Syndrome (Sjogren) - Pipeline by Novartis AG, H1 2017
  • Sicca Syndrome (Sjogren) - Pipeline by Redx Pharma Plc, H1 2017
  • Sicca Syndrome (Sjogren) - Pipeline by Samjin Pharmaceutical Co Ltd, H1 2017
  • Sicca Syndrome (Sjogren) - Pipeline by UCB SA, H1 2017
  • Sicca Syndrome (Sjogren) - Pipeline by XTL Biopharmaceuticals Ltd, H1 2017
  • Sicca Syndrome (Sjogren) - Dormant Projects, H1 2017
  • Sicca Syndrome (Sjogren) - Discontinued Products, H1 2017
  • Table of Contents
  • List of Tables
  • List of Figures
  • Introduction
  • Global Markets Direct Report Coverage
  • Sicca Syndrome (Sjogren) - Overview
  • Sicca Syndrome (Sjogren) - Therapeutics Development
  • Pipeline Overview
  • Pipeline by Companies
  • Pipeline by Universities/Institutes
  • Products under Development by Companies
  • Products under Development by Universities/Institutes
  • Sicca Syndrome (Sjogren) - Therapeutics Assessment
  • Assessment by Target
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type
  • Sicca Syndrome (Sjogren) - Companies Involved in Therapeutics Development
  • Akari Therapeutics Plc
  • Amgen Inc
  • Atlantic Bio Sci LLC
  • Bristol-Myers Squibb Company
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd
  • Galapagos NV
  • Gilead Sciences Inc
  • GlaxoSmithKline Plc
  • Immunwork Inc
  • MedImmune LLC
  • Novartis AG
  • Redx Pharma Plc
  • Samjin Pharmaceutical Co Ltd
  • UCB SA
  • XTL Biopharmaceuticals Ltd
  • Sicca Syndrome (Sjogren) - Drug Profiles
  • abatacept - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • ABS-11 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • AMG-557 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • belimumab - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • belimumab + rituximab - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • BMS-986142 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Cellular Immunotherapy for Type 1 Diabetes and Sjogrens Syndrome - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • CFZ-533 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Coversin - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • edratide - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • filgotinib - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • GS-9876 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • GSK-2618960 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • IMSO-001 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • leniolisib - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • lulizumab pegol - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • LY-3090106 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • MEDI-4920 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • MEDI-7734 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • RDX-002 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • RG-7625 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • RSLV-132 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • SA-001 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • seletalisib - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • TE-2324 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • tirabrutinib - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • VAY-736 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • VM-200 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Sicca Syndrome (Sjogren) - Dormant Projects
  • Sicca Syndrome (Sjogren) - Discontinued Products
  • Sicca Syndrome (Sjogren) - Product Development Milestones
  • Featured News & Press Releases
  • Apr 05, 2017: XTL Biopharmaceuticals Unveils Expanded hCDR1 Preclinical Data for the Treatment of Sjogren’s Syndrome
  • Apr 04, 2017: Galapagos announces three new Phase 2 Proof-of-Concept studiesbwith filgotinib
  • Feb 13, 2017: XTL Biopharmaceuticals Expands Clinical Advisory Board to Support Phase II Study of HCDR1 in Sjogren’s Syndrome
  • Jan 05, 2017: XTL Biopharmaceuticals' Preclinical Studies of hCDR1 Demonstrate Therapeutic Potental In the Treatment of Sjogren’s Syndrome
  • Apr 22, 2011: Breakthrough study links Type 1 diabetes and Sjogren’s syndrome
  • Appendix
  • Methodology
  • Coverage
  • Secondary Research
  • Primary Research
  • Expert Panel Validation
  • Contact Us
  • Disclaimer

Please select a license type

Share

Related Products

Global Markets DirectSicca Syndrome (Sjogren) - Pipeline Review, H1 2017Product ThumbnailSicca Syndrome (Sjogren) - Pipeline Review, H1 2017, Industry ReportProduct #: 829044
GlobalData
TeleResearch
Global Markets Direct
GBI Research
MarketsandMarkets
MicroMarketMonitor
PayPal Acceptance Mark
SSL Certificate
Copyright © 2017 Global Market Analyst. All Rights Reserved